Acusphere relieved by Cephalon deal
This article was originally published in Scrip
Executive Summary
Cephalonhas paid Acusphere $5 million for an exclusive worldwide licence to its preclinical-stage injectable formulation of celecoxib, Al-525. Cephalon has also bought a $15 million senior secured convertible note, providing Acusphere with some much-needed cash.